Skip to content

Potential New Treatment for Metastatic Lung Cancer

Search Clinical Trials

Trial Objectives

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, yet current treatment options are limited. In fact, the standard treatment for metastatic NSCLC has a low 5-year survival rate.

Researchers want to know if an investigational drug called SAR408701 is better than docetaxel, a chemotherapy drug already approved to treat non-small cell lung cancer (NSCLC) patients with CEACAM 5 positive tumors. The goal of this study is to determine if SAR408701 improves survival rate for NSCLC patients.

Over the course of the study, participants will have 1-2 clinic visits each month where they will receive physical exams to evaluate their response to either SAR408701 or docetaxel and monitor disease progression. Data gathered will allow researchers to track improvements in disease response, quality of life and overall symptoms to determine the effectiveness of the new drug.

Who Can Participate

Adults aged 18 years and older being treated at National Jewish Health for non-small cell lung cancer, who have progressive disease during or after at least 2 cycles of platinum-based chemotherapy and an immune checkpoint inhibitor.

Age: 18+ Gender: Any

Estimated Time Commitment

1 year

Payment & Reimbursement

Payment: Not Provided

Travel Reimbursement: Available

Trial Contact

For more information, contact:

Kris Eliopoulos

Trial Location

National Jewish Main Campus, Denver, CO

Trial Sponsors


Principal Investigators

Laurie L. Carr

Laurie L. Carr, MD

Request more Information

By completing this form, you agree to learn more about this study and see if you qualify.